Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Using lentiviral vectors to generate CAR-T cells

Sid P. Kerkar • 11 Apr 2022
AACR 2022
General CAR-T

In this video, Sid P. Kerkar, MD, Exuma Biotech, West Palm Beach, FL, discusses the generation of chimeric antigen receptor T-cells (CAR-T) in vivo by injecting lentiviral vectors into lymph nodes, a novel approach being investigated at Exuma Biotech. Dr Kerkar explains how this process is much simpler and more cost-effective than traditional manufacturing processes and the exciting impact that this research may have in the future of hematological malignancies. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Disclosures

VP of R&D at Exuma Biotech

More from Sid P. Kerkar

1:10
Cell expansion and vector design in novel T-cell therapies
Sid P. Kerkar • 11 Apr 2022
1:49
A novel subcutaneous CAR-T therapy for the treatment of hematological malignancies
Sid P. Kerkar • 11 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals